VT-101 / Fosun Pharma - LARVOL DELTA

A Clinical Trial Aimed At Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: The Affiliated Hospital of Xuzhou Medical University

New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

VT-101 injection independently developed by a subsidiary of Fosun Pharma (02196) has been approved for clinical trials [Google translation] (Stockstar) - "Fosun Pharma...announced that the company’s controlled subsidiary Jiangsu Wanbang Pharmaceutical Technology Co., Ltd. and its controlled subsidiaries...independently developed VT-101 The injection has been approved by the National Medical Products Administration and the United States The FDA (i.e., the U.S. Food and Drug Administration) has approved clinical trials of this new drug for the treatment of advanced solid tumors such as head and neck squamous cell carcinoma, melanoma, and breast cancer. Wanbang Technology plans to launch the development of this new drug in China (excluding Hong Kong, Macao and Taiwan) and the United States when conditions are met. Phase I clinical trial."

IND • New P1 trial • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck